Permanent Contact Lenses
永久隐形眼镜
基本信息
- 批准号:7483311
- 负责人:
- 金额:$ 14.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-07-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdhesionsAnimal ExperimentsAnimalsAstigmatismBindingBiochemicalBlinkingBowman&aposs MembraneChemicalsCollagenCompatibleContact LensesCorneaDevelopmentEpitheliumExcisionExposure toEyeFamily suidaeGlassGoalsHealthHumanHyperopiaImmuneImplantIn VitroLaser In Situ KeratomileusisLasersManualsMarketingModificationMoldsMyopiaOperative Surgical ProceduresPatientsPeptidesPhase I Clinical TrialsPopulationProceduresPublic HealthQuality of lifeRateRefractive ErrorsResistance to infectionSafetySurfaceTestingTissuesUltraviolet RaysVisionbiomaterial compatibilitycostdesignimplantationimprovednovelprototypesuccess
项目摘要
DESCRIPTION (provided by applicant): An estimated 2.3 billion people worldwide suffer from refractive errors such as myopia, hyperopia, and astigmatism. While glasses, traditional contact lenses, and laser surgical correction are capable of adequately treating a majority of the afflicted population, they are not without their own complications and problems. Augmentation of the natural cornea with a bio-integrated permanent contact lens would provide refractive correction with a level of safety and convenience unachievable by currently marketed products. Advantages of a bio-integrated permanent contact lens would include: 1) Implantation by a quick procedure, probably less than 20 minutes for both eyes, which does not require the removal of any stromal tissue 2) Potential for reversibility and adjustment. The contact lens although it is described as "permanent" can still be removed and replaced if necessary by peeling it away from Bowman's membrane, thus allowing adjustments in correction if necessary. 3) Greater resistance to infection because the contact lens does not require frequent manual manipulation and is covered by epithelium, the body's first line of immune defense. 4) Potentially lower cost for the patient. The contact lens could last a lifetime and does not require the use of expensive lasers as in the case of LASIK. KeraMed Inc. has developed a novel permanent contact lens which is designed to be easily implantable and bio-compatible. Our goal is to test the biocompatibility and retention of permanent contact lenses through both in vitro and vivo animal experiments. If our project is successful, we will have made a significant step towards improving human vision and quality of life. PUBLIC HEALTH SIGNFICANCE: We are developing a permanent contact lens which can be implanted safely and quickly for the correction of refractive errors. This "permanent" contact lens is also designed to be removable and replaceable if necessary.
描述(由申请人提供):估计全世界有23亿人患有近视,远视和散光等折射率。尽管眼镜,传统隐形眼镜和激光手术矫正能够充分治疗大多数受苦的人群,但它们并非没有自己的并发症和问题。通过生物融合的永久性隐形眼镜增强天然角膜,将提供屈光更正,并以当前市场上销售的产品无法获得的安全性和便利性提供折磨。生物融合的永久性隐形眼镜的优点包括:1)通过快速手术植入,两只眼睛的植入可能不到20分钟,这不需要去除任何基质组织2)潜在的可逆性和调整。尽管将其描述为“永久性”,但在必要时仍可以通过将其从鲍曼的膜中剥离,从而取代并替换,从而在必要时可以进行校正。 3)由于隐形眼镜不需要频繁的手动操作,因此对感染的阻力更大,并且被上皮覆盖,上皮是人体的第一线免疫防御。 4)患者的成本可能较低。隐形眼镜可以持续一生,不需要像Lasik那样使用昂贵的激光器。 Keramed Inc.开发了一种新型的永久性隐形眼镜,该隐形眼镜旨在易于植入和生物兼容。我们的目标是通过体外和体内动物实验测试永久性隐形眼镜的生物相容性和保留。如果我们的项目成功,我们将迈出重要的一步,以改善人类的视野和生活质量。公共卫生标志性:我们正在开发一个永久的隐形眼镜,可以安全,迅速地植入以纠正折射错误。此“永久性”隐形眼镜还旨在在必要时可移动和更换。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YICHIEH SHIUEY其他文献
YICHIEH SHIUEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YICHIEH SHIUEY', 18)}}的其他基金
Novel Keratoprosthesis Designs and Implantation Methods
新型角膜假体设计和植入方法
- 批准号:
7107629 - 财政年份:2006
- 资助金额:
$ 14.29万 - 项目类别:
相似国自然基金
早期环境暴露对儿童哮喘免疫保护的动物实验和机制研究
- 批准号:82300031
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
羊膜间充质干细胞联合水凝胶支架材料移植干预脊髓损伤动物实验研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
深渊片脚类动物原位代谢测量与高质量实验技术研究
- 批准号:42276191
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
节肢动物病毒多样性的生态驱动因素研究:以新岗山生态系统功能实验基地为例
- 批准号:32200004
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
羊膜间充质干细胞联合水凝胶支架材料移植干预脊髓损伤动物实验研究
- 批准号:82271408
- 批准年份:2022
- 资助金额:52.00 万元
- 项目类别:面上项目
相似海外基金
A reversible aptamer based therapeutic to treat stroke
基于可逆适体的中风疗法
- 批准号:
10176561 - 财政年份:2020
- 资助金额:
$ 14.29万 - 项目类别:
A reversible aptamer based therapeutic to treat stroke
基于可逆适体的中风疗法
- 批准号:
10011052 - 财政年份:2020
- 资助金额:
$ 14.29万 - 项目类别:
Bactericidal, Nonthrombogenic Intravascular Catheters
杀菌、不形成血栓的血管内导管
- 批准号:
9119055 - 财政年份:2015
- 资助金额:
$ 14.29万 - 项目类别:
Bactericidal, Nonthrombogenic Intravascular Catheters
杀菌、不形成血栓的血管内导管
- 批准号:
9316710 - 财政年份:2015
- 资助金额:
$ 14.29万 - 项目类别:
Chronic imaging of cellular dynamics after cortical microhemorrhage
皮质微出血后细胞动力学的慢性成像
- 批准号:
8719850 - 财政年份:2013
- 资助金额:
$ 14.29万 - 项目类别: